1. Inicio
  2. Publicaciones
  3. Safety and Efficacy of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Cohort Study.

Safety and Efficacy of Bimekizumab in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Multicenter Retrospective Cohort Study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Pons-Benavent M
  • Fernández-Crehuet P
  • Vilarrasa E
  • Albanell-Fernández C
  • Morales-Tedone E
  • Rausell-Félix F
  • Alcalá-García R
  • Matellanes-Palacios M
  • Martín-Ezquerra G
  • Alfageme F
  • Ciudad-Blanco C
  • López-Villaescusa MT
  • Segura-Palacios JM
  • Pascual-Ramírez JC
  • Fernández-Díaz ML
  • Falkenhain-López D
  • García-Gil M
  • Agustí-Mejías A
  • No-Pérez N
  • Naranjo-Guerrero N
  • Estenaga-Pérez Á
  • García-Ruiz R
  • Mahiques-Santos L
  • Garbayo-Salmons P
  • Martorell A
  • Cuenca-Barrales C
  • Paniego CU
  • Molina-Leyva A
  • Spanish Hidradenitis Suppurativa Grp GEHS

Grupos

Abstract

BACKGROUND: Bimekizumab is the first and only dual selective inhibitor of IL-17 A and IL-17 F that has been proven effective and safe in Phase 3 clinical trials and has been approved by the European Medicines Agency (EMA) for the treatment of hidradenitis suppurativa (HS). OBJECTIVES: To assess the safety and efficacy profile of bimekizumab in patients with moderate-to-severe HS across multiple centers in Spain. METHODS: We conducted a retrospective cohort study including 84 patients treated with bimekizumab. Efficacy was assessed using an intention-to-treat approach, with patients who discontinued treatment for any reason or were lost to follow-up considered nonresponders. Data were collected at baseline, week 16, and week 24. RESULTS: The analysis included a total of 84 patients at 16 weeks, with 43 having completed the 24-week follow-up assessment (56 men [66.67%] and 28 women [33.33%]) with a mean age of 44.17 (13.43) years and a mean baseline IHS4 of 23.75 (12.87) were included. By week 24, IHS4 scores dropped by 16.73 points (p<0.0001); a HiSCR50 of 55.95% was achieved at week 16, which was maintained with a HiSCR50 of 55.81% at week 24; DLQI scores improved by 10.67 points (p<0.0001); pain scores dropped by 3.42 points (p<0.0001); and flare counts were reduced by 1.53 (p=0.0006). Adverse events were reported in 20.24% of patients by week 16, mainly candidiasis, and dropped to 11.90% by week 24. 53.57% (45/84) of patients achieved IHS4-55 by week 16, and by week 24, 60.47% (26/43) of patients maintained or reached this response level. CONCLUSIONS: Bimekizumab is effective for the treatment of HS in real-world clinical practice, with a manageable safety profile over the 24-week period. Our findings are consistent with those reported in phase 3 clinical trials.

Copyright © 2025 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0001-7310, 1578-2190

Actas Dermo-Sifiliograficas  ELSEVIER ESPANA

Tipo:
Article
Páginas:
104531-104531
PubMed:
41354335
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
0,279 SCImago ℠
Cuartil:
Q3 SCImago ℠

Citas Recibidas en Web of Science: 2

Documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Bimekizumab; Biologic therapy; Efficacy; Hidradenitis suppurativa; Real-world evidence; Safety

Cita

Compartir